dc.contributor.author | Wright, AA | |
dc.contributor.author | Todorovic, M | |
dc.contributor.author | Tello-Velasquez, J | |
dc.contributor.author | Rayfield, AJ | |
dc.contributor.author | St John, JA | |
dc.contributor.author | Ekberg, JA | |
dc.date.accessioned | 2019-07-04T12:39:58Z | |
dc.date.available | 2019-07-04T12:39:58Z | |
dc.date.issued | 2018 | |
dc.identifier.issn | 0963-6897 | |
dc.identifier.doi | 10.1177/0963689718759472 | |
dc.identifier.uri | http://hdl.handle.net/10072/382146 | |
dc.description.abstract | Autologous olfactory ensheathing cell (OEC) transplantation is a promising therapy for spinal cord injury; however, the
efficacy varies between trials in both animals and humans. The main reason for this variability is that the purity and phenotype
of the transplanted cells differs between studies. OECs are susceptible to modulation with neurotrophic factors, and thus,
neurotrophins can be used to manipulate the transplanted cells into an optimal, consistent phenotype. OEC transplantation
can be divided into 3 phases: (1) cell preparation, (2) cell administration, and (3) continuous support to the transplanted cells in
situ. The ideal behaviour of OECs differs between these 3 phases; in the cell preparation phase, rapid cell expansion is desirable
to decrease the time between damage and transplantation. In the cell administration phase, OEC survival and integration at the
injury site, in particular migration into the glial scar, are the most critical factors, along with OEC-mediated phagocytosis of
cellular debris. Finally, continuous support needs to be provided to the transplantation site to promote survival of both
transplanted cells and endogenous cells within injury site and to promote long-term integration of the transplanted cells and
angiogenesis. In this review, we define the 3 phases of OEC transplantation into the injured spinal cord and the optimal cell
behaviors required for each phase. Optimising functional outcomes of OEC transplantation can be achieved by modulation of
cell behaviours with neurotrophins. We identify the key growth factors that exhibit the strongest potential for optimizing the
OEC phenotype required for each phase. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Cognizant Communication Corp. | |
dc.publisher.place | United States | |
dc.relation.ispartofpagefrom | 867 | |
dc.relation.ispartofpageto | 878 | |
dc.relation.ispartofissue | 6 | |
dc.relation.ispartofjournal | Cell Transplantation | |
dc.relation.ispartofvolume | 27 | |
dc.subject.fieldofresearch | Biological sciences | |
dc.subject.fieldofresearch | Other biological sciences not elsewhere classified | |
dc.subject.fieldofresearch | Biomedical and clinical sciences | |
dc.subject.fieldofresearchcode | 31 | |
dc.subject.fieldofresearchcode | 319999 | |
dc.subject.fieldofresearchcode | 32 | |
dc.title | Enhancing the Therapeutic Potential of Olfactory Ensheathing Cells in Spinal Cord Repair Using Neurotrophins | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
dc.description.version | Version of Record (VoR) | |
gro.faculty | Griffith Sciences, Griffith Institute for Drug Discovery | |
gro.rights.copyright | © 2018 Cognizant Communication Corporation. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version. | |
gro.hasfulltext | Full Text | |
gro.griffith.author | St John, James A. | |
gro.griffith.author | Ekberg, Jenny A. | |
gro.griffith.author | Rayfield, Andrew J. | |